ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0457

Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening
Abstract Number: 0458

TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Abstract Number: 0459

Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Abstract Number: 0460

The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Abstract Number: 0461

Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Abstract Number: 0462

Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
Abstract Number: 0463

Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Abstract Number: 0464

Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Abstract Number: 0465

Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Abstract Number: 0466

Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Abstract Number: 0467

A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
Abstract Number: 0468

Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA) in a nationwide multicenter Chinese cohort
Abstract Number: 0469

Evaluating Large Language Models for Automated Joint Involvement Analysis in Rheumatoid Arthritis
Abstract Number: 0470

Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Abstract Number: 0471

An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].